🔗 Permalink

Inventor profile of:

Laurence Elias

City:

Berkeley, California

Country:

United States

Published Applications:

Last publication date:

2025-04-24

Top Assignees for applications by Laurence Elias

The entities that hold a legal rights for patent applications filed by inventor Elias Laurence:

Pharmacyclics, Inc 11 Sunnyvale, CA United States
PHARMACYCLICS, LLC. 11 Sunnyvale, CA United States
Geron Corporation 3 Menlo Park, CA United States
Novartis Vaccines and Diagnostics, Inc. 1 Emeryville, CA United States
Chiron Corporation 1 Emeryville, CA United States

Recent patent applications by Elias Laurence

Laurence Elias from Berkeley, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-04-24

US20250127781A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#2 | 2024-09-26

US20240318232A1

Chemistry; metallurgy

Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy

#3 | 2023-04-13

US20230114322A1

Chemistry; metallurgy

Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy

#4 | 2022-10-13

US20220325327A1

Chemistry; metallurgy

Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy

#5 | 2022-08-11

US20220249494A1

Human necessities

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

#6 | 2022-06-09

US20220175785A1

Human necessities

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

#7 | 2021-11-25

US20210361657A1

Human necessities

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

#8 | 2021-09-02

US20210269861A1

Chemistry; metallurgy

Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy

#9 | 2021-05-20

US20210145835A1

Human necessities

METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER

#10 | 2020-09-03

US20200276199A1

Human necessities

INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS

#11 | 2019-12-19

US20190382829A1

Chemistry; metallurgy

Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy

#12 | 2019-06-06

US20190167687A1

Human necessities

METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER

#13 | 2018-10-04

US20180280395A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#14 | 2018-09-13

US20180256581A1

Human necessities

Use of inhibitors of bruton's tyrosine kinase (Btk)

#15 | 2018-07-12

US20180193345A1

Human necessities

INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS

#16 | 2018-03-15

US20180071294A1

Human necessities

Methods for the treatment of HER2 amplified cancer

#17 | 2018-02-08

US20180036313A1

Human necessities

Use of inhibitors of Bruton's tyrosine kinase (Btk)

#18 | 2018-01-18

US20180015091A1

Human necessities

Use of inhibitors of Bruton's tyrosine kinase (Btk)

#19 | 2017-10-19

US20170298421A1

Chemistry; metallurgy

Method for identification of sensitivity of a patient to telomerase inhibition therapy

#20 | 2017-09-21

US20170266186A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#21 | 2017-06-01

US20170151243A1

Human necessities

Methods for the treatment of HER2 amplified cancer

#22 | 2017-02-09

US20170035762A1

Human necessities

Use of inhibitors of Bruton'S tyrosine kinase (Btk)

#23 | 2016-11-10

US20160324859A1

Human necessities

Use of inhibitors of bruton's tyrosine kinase (BTK)

#24 | 2016-06-23

US20160175312A1

Human necessities

Use of inhibitors of bruton's tyrosine kinase (Btk)

#25 | 2016-01-07

US20160000792A1

Human necessities

Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors

#26 | 2015-06-04

US20150152488A1

Chemistry; metallurgy

Method for identification of sensitivity of a patient to telomerase inhibition therapy

#27 | 2015-02-12

US20150044217A1

Human necessities

Methods for the treatment of HER2 amplified cancer

#28 | 2015-01-29

US20150031711A1

Chemistry; metallurgy

Use of inhibitors of Bruton's tyrosine kinase (Btk)

#29 | 2015-01-29

US20150031710A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#30 | 2014-10-09

US20140303191A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#31 | 2014-07-10

US20140194446A1

Chemistry; metallurgy

Use of inhibitors of bruton's tyrosine kinase (BTK)

#32 | 2014-03-20

US20140079690A1

Human necessities

Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumors

#33 | 2013-11-21

US20130310402A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#34 | 2013-10-17

US20130273030A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#35 | 2013-08-08

US20130202611A1

Chemistry; metallurgy

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#36 | 2013-08-01

US20130195852A1

Human necessities

Use of inhibitors of Bruton's tyrosine kinase (Btk)

#37 | 2012-07-19

US20120183535A1

Human necessities

Use of inhibitors of bruton's tyrosine kinase (Btk)

#38 | 2012-04-26

US20120100138A1

Human necessities

THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#39 | 2012-04-12

US20120087915A1

Human necessities

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

#40 | 2011-10-27

US20110263685A1

Chemistry; metallurgy

Method for identification of sensitivity of a patient to telomerase inhibition therapy

#41 | 2010-12-16

US20100316595A1

Human necessities

Methods for treating renal cell carcinoma

InventorID:

364742 ⎘